Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13656164 | 0.98 | CYP2D6 (0.34) | CYP2D6HTR1ACYP1A2ALOX15ADRA1B | |
| SCHEMBL19962321 | 0.96 | CYP1A2 (0.32) | CYP2D6HTR1ACYP1A2ALOX15ADRA1B | |
| SCHEMBL26455588 | 0.91 | CYP2D6 (0.37) | CYP2D6CYP1A2ALOX15SMN1; SMN2 | |
| SCHEMBL24842172 | 0.89 | CYP2D6 (0.36) | CYP2D6CYP1A2ALOX15SMN1; SMN2 | |
| SCHEMBL19962318 | 0.88 | HSD11B1 (0.36) | CYP2D6CYP1A2HSD11B1 | |
| SCHEMBL12228922 | 0.83 | CYP2D6 (0.37) | CYP2D6CYP1A2ALOX15SMN1; SMN2 | |
| SCHEMBL23594395 | 0.81 | GRIN2D (0.36) | CYP2D6CYP1A2ALOX15SMN1; SMN2 | |
| SCHEMBL26455582 | 0.80 | TSHR (0.36) | CYP2D6CYP1A2ALOX15 | |
| SCHEMBL19962314 | 0.79 | CYP2D6 (0.35) | CYP2D6CYP1A2HSD11B1SMN1; SMN2 | |
| SCHEMBL23075935 | 0.79 | CYP1A2 (0.45) | CYP2D6CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072677-A1 | Peptidomimetics and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-03-15 | — | — | US | disclosed |
| US-7605176-B2 | β-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-20 | — | — | US | disclosed |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | CYP2D6 2280/4885HTR1A 155/4885CYP1A2 1859/4885 |
| US-20180072677-A1 | Peptidomimetics and Methods of Using the Same | OPRM1, OPRL1, OPRD1 | CYP2D6 663/4885HTR1A 226/4885CYP1A2 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.